Statins and acute lung injury: holy Grail or the next to fail?*
A cute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS) are life-threatening critical care syndromes that continue to consume substantial healthcare resources and profoundly impact patient-important outcomes (1). Although recent epidemiologic studies suggest the incidence of lung injury may be on the decline (2), even conservative estimates suggest the associated mortality continues to exceed 25% (3). Mechanistically, the "lung attack" is characterized by abrupt injury to the alveolar-capillary barrier with resultant alveolar flooding and hypoxemic respiratory failure. Although our understanding of the precise mechanisms underlying this process continues to unfold, the available data suggest critical roles for inflammation, endothelial activation and injury, epithelial injury, intravascular coagulation, and oxidative stress.
To date, substantial effort has been expanded in an attempt to identify effective therapeutic options for patients with this serious critical care syndrome. Although numerous therapeutic interventions have shown great initial promise, such as N-acetylcysteine (4), ketokonazole (5), lisofylline (6), sivelestat (7) , and, more recently, inhaled b-agonists (8) and omega-3 fatty acids (9), translation to clinical benefit has been frustratingly elusive. Despite our best efforts, we are mostly left with the avoidance of additional lung injury via protective ventilator settings (10) and conservative fluid approaches (11) as our only supportive therapies.
HMG-CoA reductase inhibitors (statins) are a class of medications that have been traditionally recommended and prescribed for the treatment of hypercholesterolemia and for the secondary prevention of cardiovascular disease (12, 13) . More recently, statins have been shown to possess a variety of nonlipid-lowering effects, termed the pleiotropic effects of statin therapy. These nonlipid-lowering properties are believed to affect a diverse set of cellular and metabolic pathways, including inflammatory, oxidative, and thrombotic processes (14) . The characterization of these pleiotropic effects has led to the study of statins in a wide range of disease processes, including cerebrovascular (15) and renal disease (16), cancer (17), venous thromboembolism (18), and a variety of infectious complications including bacteremia (19), pneumonia (20), and sepsis (21).
In light of the substantial concordance between our understanding of ALI pathophysiology and the described pleiotrophic effects of statin therapy, a potential role for statins in the mitigation of ALI development and progression would certainly seem plausible as well. Furthermore, there is wealth of preclinical data that support a role for statins in this setting (22) . Importantly, however, we have been here before, and the history of ALI therapeutics has been quite unforgiving. So, with a healthy degree of skepticism we ask, "Will the promising preclinical data regarding statins translate into clinical benefit?" Until now, there had been three observational studies (23-25) and two phase I/ II clinical trials (26, 27) , all aiming to address the role of statins in the prevention or treatment of ALI. In the three investigations addressing statins in patients with established lung injury, the results have been inconsistent and mostly underwhelming (23, 24, 27) . Intuitively, we might expect to see improved efficacy with the administration of statins in patients at risk for ALI as compared to those with the fully established syndrome. Two recent investigations have specifically evaluated this question. In a small, randomized, clinical trial of 30 healthy volunteers, Shymansunder et al (26) evaluated the impact statin pretreatment had on the inflammatory response in healthy volunteers who inhaled lipopolysaccharide.
When compared to the placebo group, the statin cohort was noted to have an attenuated inflammatory response. In a second observational cohort study, O'Neal et al (25) reported a reduced incidence of ALI in critically ill patients using chronic statin therapy. This protective affect was most notable in those with sepsis and the affect appeared to be potentiated by the coadministration of aspirin. Notably, prehospital statin use was not associated with improvements in patient-centered outcomes such as ventilator-free days or intensive care unit or hospital length of stay.
Several limitations exist in each of the aforementioned investigations. Both clinical trials were performed in a single center and were of limited sample size. The initial trial (26) enrolled healthy volunteers and the subsequent investigation noted improved late organ failures, but no improvements in early organ failures or pulmonary or patient-important outcomes at any point during the assessment period (27). The observational studies also have been generally limited by small sample size, indication bias, incomplete adjustment of confounding variables, and incomplete characterization of statin administration. Furthermore, differing study populations with varying ALI risk profiles, differing study methodologies, inconsistent outcome definitions, and widely disparate statin dosing regimens preclude meaningful between-study comparisons.
In this issue of Critical Care Medicine, Dr. Bajwa and colleagues (28) aimed to shed additional light on the role of statins in the prevention and treatment of ALI. The primary objective of the study was to evaluate the association between statin administration within 24 hrs of intensive care unit admission and development of ARDS in a high-risk intensive care unit cohort. As a secondary aim, the investigators assessed the impact of statin therapy on patient-centered outcomes after development of ARDS. The initial results were encouraging because statin administration was associated with a reduced incidence of ARDS. However, the initial enthusiasm would prove fleeting because the association was lost in the more robust propensity-adjusted analyses. Furthermore, when evaluating patient-centered outcomes in those who had development of ARDS, no benefits were seen in the statin cohort.
To what extent does the current investigation (28) refute a role for statins in the prevention and treatment of ALI? At the least, it should cast a substantial shadow of doubt. Although previous studies have adjusted for confounding variables, none have included as detailed a statistical plan. The propensity models were robust, well-thought, and effective in establishing baseline covariate balance. In addition, the sample size was large and the study population closely matched what most would agree is the desired target population, specifically, critically ill patients with major risk factors for ALI.
The study of Dr. Bajwa and colleagues (28) was performed well and it addressed a number of the previously identified concerns. However, important limitations and several questions do remain. The observational nature of the investigation cannot rule out the potential influence of additional unmeasured confounding affects. In addition, most patients (92%) had their statin therapy discontinued after admission to the intensive care unit. The impact of this practice on patient outcomes is unknown and will clearly require additional study. Potentially important details relating to the intervention of interest (e.g., specific statin agent administered, dosing regimen, and others) are also lacking. Finally, a pervasive limitation in the study of ALI interventions is the ongoing desire to characterize the syndrome as a single disease entity. We must remember, ALI is not a well-characterized disease. Rather, it is a syndrome that arises in widely disparate clinical scenarios. Is it reasonable to expect that statin administration would be as effective for the prevention of ALI in patients with an aspiration event or a major surgical procedure as it is in the setting of septic shock? If we are to make meaningful progress in the prevention and treatment of ALI, it may well be time to begin evaluating the impact of preventive strategies and therapeutic interventions in specific clinical constructs rather than in the unified whole.
And so here we are now, more uncertain of the role of statins in ALI than ever before. As we await the results of more definitive clinical trials, such as Statins for Acutely Injured Lungs From Sepsis (SAILS; Clinicaltrials.gov ID: NCT00979121) and Simvastatin Effect on the Incidence of Acute Lung Injury/ Adult Respiratory Distress Syndrome (ALI/ARDS; Clinicaltrials.gov ID: NCT01195428), we hold out hope that statins are indeed the Holy Grail. However, I would advise a degree of caution as we anxiously await these study results. M ortality from severe sepsis and septic shock in adults is still considered high on the order of 18% to 46% (1-3). Interest in the pathophysiological relationship among arachidonic acid (AA), its metabolites, and sepsis has been with us now for 30 yrs (4). During this period there has been a staggering amount of published scientific and clinical research. The U.S. National Library of Medicine National Institutes of Health alone returns 113,883 articles to the search term "sepsis" or "septic shock" and 23,412 articles to the term "septic shock" (5). Despite this wealth of knowledge on the progression of sepsis toward death, current therapeutic strategies to improve survival by and large have not been successful. The question that we must continually ask is why? There are many answers.
Although the pathophysiology of sepsis is complex, current evidence suggests that the proinflammatory response is excessive and that attenuating this response should provide benefit to the patient in terms of recovery from inflammation and improved survival. In patients with sepsis, the enzyme cyclo-oxygenase (COX) causes an increase in the production of AA metabolites, some of which are thought to be proinflammatory. The anti-inflammatory agent, ibuprofen, inhibits COX, and in animal models, such treatment before the onset of sepsis has been shown to improve survival, yet in larger clinical trials, although there was some reduction in metabolic acidosis and some inflammatory signs, nevertheless there was no significant improvement in mortality (1). Respir Crit Care Med 2009; 179:1107 -1114 Science, sceptics, sepsis, and simplicity*
The article by Bruegel and others (6) in this issue of Critical Care Medicine is important on a number of counts. First, it provides some explanation at the "downstream" molecular level as to why COX inhibitors such as ibuprofen may not have been as effective as expected in critically ill patients with sepsis. Second, it also investigates the differential regulation and expression of the upstream target genes responsible for AA metabolism-COX-2 and microsomal prostaglandin E synthase-1 (MPGES-1)whose messenger RNA expression is responsible for producing sufficient quantities of the enzymes: COX and prostaglandin E synthase-1. The aims of this study were first to screen for differential regulation of AA metabolites, second to investigate the early diagnostic potential of these changes to predict 2-wk disease severity and prognosis, and third to explore the upstream genetic expression and differential regulation of target genes of AA metabolism. However, in the course of their study, the investigators made some interesting observations, which may help explain the lack of effectiveness of nonsteroidal anti-inflammatory drugs to improve survival in septic patients and may guide the direction of future research.
This was primarily an exploratory study designed not so much to provide definitive answers to important clinical questions of diagnosis, but to provide some explanation as to why therapeutic strategies may fail and also to stimulate thought for new avenues for research. Written by clinical scientists with a special interest in the field of AA metabolism rather than the general or intensive care clinician, the article is not easy to read. It was Albert Einstein who said, "Everything should be made as simple as possible, but not simpler." The application of this quote depends to some extent on the nature of the audience or reader, and for further background on this article, the reader may turn to the web for a brief but relevant summary on AA metabolism and eicosanoids (7).
The authors state that they aimed to investigate the diagnostic potential of AA metabolites in patients with sepsis. This may indeed be the case from the perspective of the scientist, but from the perspective of the diagnostic researcher, the investigators do not define a gold standard and do not follow STAndards for the Reporting of Diagnostic accuracy studies criteria (8). Thus, their findings cannot be useful diagnostically. In fact, their article really aimed to identify prognostic markers of prolonged intensive care unit care or death rather than diagnostic markers for sepsis. The investigators did not use a milder group of septic patients as control subjects, which would have been more appropriate than healthy control subjects.
Based on previous work, it was expected that septic patients possess leukocytes that are highly COX-active and that inhibiting the COX effect by a drug such as ibuprofen would prevent the excessive proinflammatory effect, thus improving the patient's chances of survival (9-11). Bruegel et al did not investigate the effect of ibuprofen or COX inhibitors on their whole blood samples, but they did find that AA metabolites were lower in septic patients than in healthy control subjects. Although lipopolysaccharide had some positive effect on the production of AA metabolites in critically ill septic patients, this effect was lower than in control subjects suggesting that the effect of COX may already be muted in such patients and that there may be little need to inhibit it further. If the COX effect is already inhibited from an early stage of illness in critically ill septic patients with a poor prognosis, then it is reasonable to speculate that there is little COX responsiveness remaining for ibuprofen to inhibit. This may be one further reason for the negative outcome in the ibuprofen-sepsis trials.
